Mentice receives order of total SEK 7.1 million from ABBOTT

Report this content

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has entered into an agreement with ABBOTT to provide simulation solutions for training of interventional devices.

The initial order covers systems and development to be delivered during the fourth quarter 2020 and in 2021. These systems will be offered under a rental agreement with a 2-year term and the company will accordingly account for revenue under the same period.

The solutions will support ABBOTT in the work of rolling out a range of new medical devices to the market in a safe and effective way. 

The order will be accounted for in the order book for the segment Medical Device Industry during the fourth quarter 2020. The total value for the order amounts to SEK 7.1 million.

For more information, please contact:
Göran Malmberg, CEO, Mentice

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. More information on

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 10.00 on October 23, 2020.  

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399


Documents & Links